Essays & long-form
Long-form on chemical safety data, regulatory consensus, marketplace screening, and why ALETHEIA exists. Each one is dated, sourced against primary regulation, and worth reading even if you never touch the API.
What's wrong with PubChem and EPA CompTox for the screening use case — and why the next layer is a synthesis that preserves disagreement between agencies rather than picking one source.
An honest side-by-side. Includes the "you don't need us" rows — when PubChem or CompTox is the better tool and why.
Three approaches to programmatic ingredient screening (build in-house / license a regulatory database / cross-agency consensus API). When each one wins. Sized for marketplaces between 800 and 8,000+ new listings per day.
A worked example: how the GeodesicNexus network of 7 consumer-safety apps (baby, body, food, home, pets, outdoor, water) shares a single ALETHEIA integration. Compound-as-shared-substrate architecture, regulator context next to claims, and write-time cross-linking.
The original 26 substances from the 2003 amendment, the two banned outright (Lyral 2021, Lilial 2022), and the 56 new entries added by Regulation 2023/1545 with the 31 July 2026 / 31 July 2028 transition timeline. INCI cheat sheet + pre-flight checklist for brands and marketplaces. Downloadable as a 14-page PDF.
The synthesis layer rendered as a 5-axis pentagon: Magnitude, Confidence, Recency, Methodology, Specificity. Why "consensus" alone isn't enough, and how preserving inter-agency disagreement is more honest than averaging it out. Worked examples: glyphosate, theobromine, lead.
Our cadence: we write essays when we have something to say, not on a schedule. Roughly one substantive piece per month. If you'd like to be notified of new essays, drop your address in any of the guide forms or via the contact form — we won't add you to any other list.